Neoplasms

All Conditions

Digestive System Diseases

Infections

Symptoms and General Pathology

Rare Diseases

Carcinoma

Carcinoma, Hepatocellular

Hepatitis A

Hepatitis

Hepatitis B

Hepatitis B, Chronic

Liver Neoplasms

Hepatitis, Chronic

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Liver Diseases

Gastrointestinal Diseases

Hepatitis, Viral, Human

Virus Diseases

Communicable Diseases

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Blood-Borne Infections

Hepadnaviridae Infections

DNA Virus Infections

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Hematinics

All Drugs and Chemicals

Anti-Infective Agents

Antineoplastic Agents

Liver Extracts

Tenofovir

Interferons

Entecavir

Antiviral Agents

Reverse Transcriptase Inhibitors

Enzyme Inhibitors

Anti-HIV Agents

Anti-Retroviral Agents

patients receive NAs（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） combine with interferon treatments for 48weeks, and then continue NAs treatment

patients receive NAs treatment（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"）

NAs（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"）

NAs（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） combined with interferon treatments

patients receive NAs（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） treatment at least 48 weeks

NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） treatments

yanfang wu

yanfang wu, master

boheng zhang

The goal of this clinical trial is to test the outcomes of HBsAg(+) patients in the treatments of NAs vs NAs plus IFN . The main questions it aims to answer are:

1. Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment;
2. Repetitive effect and time effect of different drug treatment at different follow-up time points;
3. To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon;
4. Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination.

Researchers will compare control group to see if occurrence of liver cancer.

Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

To compare the incidence of early liver cancer in different treatment groups

Zhongshan Hospital (Xiamen), Fudan University

Spots Global Cancer Trial Database for chronic hepatitis b (chb)